Cerebral venous thrombosis in women of childbearing age: diagnosis, treatment, and prophylaxis during a future pregnancy.
Büșra DurmușLaetitia YperzeeleSusanna M ZuurbierPublished in: Therapeutic advances in neurological disorders (2020)
Sex-specific risk factors for cerebral venous thrombosis (CVT) in women include oral contraceptives, pregnancy, puerperium, and hormone replacement therapy. The acute treatment of CVT is anticoagulation using therapeutic doses of low molecular weight heparin, which is also the preferred treatment in the post-acute phase in pregnancy and during breastfeeding. In patients with imminent brain herniation decompressive surgery is probably life-saving. A medical history of CVT alone is not a contraindication for future pregnancies. The optimal dosage of low molecular weight heparin as thrombosis prophylaxis during future pregnancies after a history of venous thrombosis including CVT is the topic of an ongoing trial.
Keyphrases
- pregnancy outcomes
- replacement therapy
- preterm birth
- venous thromboembolism
- minimally invasive
- clinical trial
- randomized controlled trial
- atrial fibrillation
- subarachnoid hemorrhage
- traumatic brain injury
- preterm infants
- intensive care unit
- study protocol
- cerebral ischemia
- resting state
- acute coronary syndrome
- cervical cancer screening